Gapping down
In reaction to disappointing earnings/guidance: IPCI -10.3%, ACTS -5.5%, ACLS -3.1%.
Select financial related names showing weakness: NBG -3.5%, ING -2.4%, LYG -2.3%, UBS -1.5%, BCS -1.3%, DB -1.3%, SAN -0.9%, CS -0.9%, HSBC -0.9%, .
Select Airline related stocks trading lower following Air France lowered guidance: DAL -1.5%, JBLU -1.4%, LUV -1.1%.
Other news: ZGNX -8.5% (following FDA granting priority review designation for Purdue Pharma's once-daily hydrocodone Bitartrate Extended-Release tablets formulated with abuse-deterrent properties news), CAMT -6.2% (pulling back from yesterday's advance), USU -5.5% (Court approves USEC disclosure statement; Chapter 11 process moves forward; Voting on Plan of Reorganization begins soon), SDRL -3.5% (launches $1 billion 2019 convertible bond concurrently with a voluntary incentive payment offer to convert the existing $650 million 3.375% convertible bond due 2017), BLUE -3% (commenced an underwritten public offering of $100 million of its common stock, PSTI -2.6% (initiates South Korean Arm of multinational Phase II Intermittent Claudication trial ), CGEN-2.3% (still checking), TAT -1.3% (co announced that net sales for the second quarter of 2014 are expected to be slightly lower than net production), TSLA -0.9% (target of trademark infringement case, according to reports out overnight).
Analyst comments: TFM -6.2% (downgraded to Sell from Neutral at Goldman), CSC -0.6% (initiated with a Underweight at Morgan Stanley).
In reaction to disappointing earnings/guidance: IPCI -10.3%, ACTS -5.5%, ACLS -3.1%.
Select financial related names showing weakness: NBG -3.5%, ING -2.4%, LYG -2.3%, UBS -1.5%, BCS -1.3%, DB -1.3%, SAN -0.9%, CS -0.9%, HSBC -0.9%, .
Select Airline related stocks trading lower following Air France lowered guidance: DAL -1.5%, JBLU -1.4%, LUV -1.1%.
Other news: ZGNX -8.5% (following FDA granting priority review designation for Purdue Pharma's once-daily hydrocodone Bitartrate Extended-Release tablets formulated with abuse-deterrent properties news), CAMT -6.2% (pulling back from yesterday's advance), USU -5.5% (Court approves USEC disclosure statement; Chapter 11 process moves forward; Voting on Plan of Reorganization begins soon), SDRL -3.5% (launches $1 billion 2019 convertible bond concurrently with a voluntary incentive payment offer to convert the existing $650 million 3.375% convertible bond due 2017), BLUE -3% (commenced an underwritten public offering of $100 million of its common stock, PSTI -2.6% (initiates South Korean Arm of multinational Phase II Intermittent Claudication trial ), CGEN-2.3% (still checking), TAT -1.3% (co announced that net sales for the second quarter of 2014 are expected to be slightly lower than net production), TSLA -0.9% (target of trademark infringement case, according to reports out overnight).
Analyst comments: TFM -6.2% (downgraded to Sell from Neutral at Goldman), CSC -0.6% (initiated with a Underweight at Morgan Stanley).